PPAR Research
Volume 2016 (2016), Article ID 5716415, 5 pages
http://dx.doi.org/10.1155/2016/5716415

Research Article

Natalizumab Treatment Modulates Peroxisome Proliferator-Activated Receptors Expression in Women with Multiple Sclerosis

Véronique Ferret-Sena,¹ Alexandra Maia e Silva,¹ Armando Sena,1,2 Inês Cavaleiro,¹ José Vale,³ Bruno Derudas,⁴ Giulia Chinetti-Gbaguidi,4,5 and Bart Staels⁴

¹Interdisciplinary Centre of Research Egas Moniz (CiiEM), Caparica, Portugal
²Neurology Service, Hospital dos Capuchos, Centro Hospitalar Lisboa Central, Lisboa, Portugal
³Department of Neurology, Hospital Beatriz Angelo, Loures, Portugal
⁴University of Lille, Inserm, CHU Lille, Institut Pasteur de Lille, Lille, France
⁵University of Côte d’Azur, CHU, CNRS, Inserm, IRCAN, Nice, France

Received 9 September 2016; Accepted 24 November 2016

Academic Editor: Pascal Froment

Copyright © 2016 Véronique Ferret-Sena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors suggested to be involved in inflammatory lesions of autoimmune encephalomyelitis and multiple sclerosis (MS). Our objective was to assess whether Natalizumab (NTZ) therapy is associated with alterations of PPAR expression in MS patients. We analyzed gene expression of PPAR in peripheral blood mononuclear cells (PBMC) as well as blood inflammatory markers in women with MS previously medicated with first-line immunomodulators (baseline) and after NTZ therapy. No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression were found in PBMC between patients under baseline and healthy controls. At three months, NTZ increased PPARβ/δ mRNA () in comparison to baseline, while mRNA expression of PPARγ and CD36 (a well-known PPAR target gene) was lower in comparison to healthy controls ( and , resp.). Although these trends of alterations remain after six months of therapy, the results were not statistically significant. Osteopontin levels were elevated in patients () and did not change during the follow-up period of NTZ treatment. These results suggest that PPAR-mediated processes may contribute to the mechanisms of action of NTZ therapy.

1. Introduction

Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central nervous system. It is generally accepted that migration of autoreactive T cells and monocytes across the blood-brain barrier (BBB) is of critical importance for the pathogenesis of the disease. Peroxisome Proliferator-Activated Receptors (PPAR) are transcription factors involved in metabolic and immune processes [1] and regulate T cell-mediated autoimmunity and severity of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) [2–4]. In MS patients, peripheral blood mononuclear cells (PBMC) exhibit decreased PPARγ expression inversely correlated with disease activity and PPARγ agonists may have beneficial effects [4–6]. Some studies have suggested that PPARα [2] and PPARβ/δ [7] specific agonists should also be considered as possible therapeutic strategies for this disorder.

In the present exploratory study we analyzed patients treated with Natalizumab (NTZ), a humanized monoclonal antibody against α4 integrin molecules that inhibits transmigration of leukocytes to the CNS and induces complex alterations of immune functions in peripheral circulation [8–10]. However, the mechanisms underlying the beneficial effects and potential adverse events of this treatment in MS are not fully understood. Based on the literature, we hypothesized that NTZ therapy could change PPAR and CD36 gene expression in PBMC. CD36 is an innate immune receptor expressed in endothelial cells and microglia/macrophages upregulated by PPARγ [1]. Blood levels of metalloproteinase-9 (MMP-9), neopterin, and osteopontin (OPN) were also measured, since their expression may be modulated by PPAR [1] and MS therapies [8, 11, 12].

2. Material and Methods

2.1. Patients

Twelve female patients, with relapsing-remitting MS (RRMS) and scheduled to start treatment with NTZ, were recruited from two MS clinical centers in Lisbon (Portugal). The mean age of these patients was 43 years (SD: 12); the mean duration of the disease 11.6 years (SD: 8.8); the mean expanded disability status scale is 4.1 (SD: 1.9); and the annualized relapse rate is 2.9 (SD: 1.7). The mean annualized relapse rate was calculated on the basis of the number of relapses occurring in each subject the previous two years under first-line immunomodulator treatment. Eleven patients received interferon beta-1a (Rebif, 44 μg s.c.) 3 times weekly or interferon-1b (Betaferon, 250 μg s.c.) every other day. One patient was medicated with glatiramer acetate injections. Blood samples were collected from these patients after a one-week washout period before starting treatment with 300 mg NTZ intravenously once monthly (baseline). At sampling, no patient was suffering from a relapse nor taking lipid-lowering agents and none had been treated with steroids for at least 1 month. Blood samples were also obtained at three and six months after switching therapy, just before the infusion of NTZ. During this study period, no patient suffered from a relapse or was medicated with corticosteroids. All patients and nine age-matched female healthy controls signed an informed consent. The local Ethics Committee approved this study.

2.2. RNA Extraction and PCR Analysis

Blood was processed immediately after venipuncture and PBMC were collected by a lymphocyte separation medium gradient. Purification of mRNA was processed using QIAamp RNA Blood Mini Kit (Qiagen), according to the manufacturer’ protocol. PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression in PBMC was evaluated by quantitative RT-PCR. RNA was reverse-transcribed using random hexamer primers and Superscript reverse transcriptase (Life Technologies, France) and cDNAs were quantified either by Brilliant III Ultra-Fast SYBRGreen using specific oligonucleotides (for PPARγ, CD36 and cyclophilin) or by Kit Brilliant Multiplex QPCR Master Mix Agilent to simultaneously detect the expression of PPARα, PPARβ/δ, and cyclophilin on an Mx3000 apparatus (Stratagene, La Jolla, CA) (see Supplementary Information available online at http://dx.doi.org/10.1155/2016/5716415 for primers and probes used). The relative expression of each gene was calculated by the ΔCt method, where ΔCt is the value obtained by subtracting the Ct (threshold cycle) value of cyclophilin mRNA from the Ct value of the target gene. The amount of target relative to the cyclophilin mRNA was expressed as .

2.3. Biochemistry Assays

Plasma and serum were collected from the same samples and stored at −80°C until use. Commercially available enzyme-linked immunosorbent assays (ELISA) were used for measurement of MMP-9, OPN (Quantikine ELISA Kits, R&D Systems Europe, Abingdon, UK), and neopterin (ELISA Kit, IBL, Hamburg, Germany).

2.4. Statistical Analysis

Expression of PPARα, PPARβ/δ, PPARγ, and CD36 mRNA and inflammatory marker concentrations were compared between patients and healthy controls using two-sample -tests. The change from baseline in these parameters at three and six months on NTZ therapy was analyzed using one-sample -tests. The correlations between the changes in PPAR expression and the changes in inflammatory mediators were carried out using Pearson’s correlation coefficient. A value < 0.05 was considered statistically significant.

3. Results

The results concerning PPAR and CD36 mRNA in the PBMC of the studied population are presented in Figure 1. No differences in PPARα, PPARβ/δ, PPARγ, and CD36 mRNA expression between patients under baseline treatment and healthy controls were found. At three months on NTZ, patients had higher PPARβ/δ mRNA expression in comparison to baseline (mean difference 14.5 (95% CI: 4.4, 24.6), ). In addition, NTZ treated patients had lower PPARγ (difference in means −64 (95% CI: −120, −9), ) and CD36 (difference in means −32 (95% CI: −60, −4), ) mRNA expression at three months than normal controls. CD36 level was also lower in comparison to baseline (mean difference −32 (95% CI: −60, −4), ). Although this trend of alterations remained after six months on NTZ therapy the results were not statistically significant. In contrast, this treatment did not change PPARα gene expression in PBMC.

(a)

(b)

(c)

(d)

Figure 1: Expression of PPARα, PPARβ/δ, PPARγ, and CD36 in PBMC of healthy controls and patients. PBMC were isolated from healthy controls and patients at baseline and after 3 (T3) or 6 months (T6) of treatment with NTZ. mRNA levels of PPARα (a), PPARβ/δ (b), PPARγ (c), and CD36 (d) were measured by Q-PCR. The relative expression of each gene was calculated as described above, normalized to cyclophilin mRNA, and expressed as means ± SD relative to healthy controls set at 100.

Plasma concentrations of inflammatory markers are presented in Table 1. No statistically significant differences in MMP-9 protein levels between patients and healthy controls were found. Patients under baseline had higher neopterin levels than healthy controls (difference in means 3.9 (95% CI: 0.4, 7.3), ). NTZ therapy decreased neopterin to normal levels. Patients had higher OPN levels than healthy controls under baseline (difference in means 53 (95% CI: 23, 84), ) and at three months (difference in means 30 (95% CI: 10, 50), ) and six months (difference in means 33 (95% CI: 10, 56), ) on NTZ therapy. No statistically significant correlations between the changes in PPAR expression and the changes of inflammatory mediators were observed (data not shown). These results remain unchanged whether the patient who received glatiramer acetate treatment was excluded from the analysis.

Table 1: Inflammatory markers.

Markers
Healthy
controls
MS patients

Baseline treatment
Natalizumab

3 months

6 months

MMP-9
636.3 (349.9)
565.7 (280.7)
0.613
474.7 (214.1)
0.205
0.446
467.2 (209.2)
0.385

Neopterin
5.7 (1.4)
9.6 (4.8)
0.029
6.6 (1.4)
0.144
0.033
6.0 (0.5)
0.018

Osteopontin
51.1 (18)
104.1 (40.6)
0.002
81 (24.5)
0.006
0.073
84.2 (29.1)
0.225

Values shown are mean (± SD) ng/mL.

—comparison between patients at baseline and healthy controls.

—comparison between patients at three months on Natalizumab therapy and healthy controls.

—comparison between patients at baseline and at three months on Natalizumab therapy.

—comparison between patients at baseline and at six months of Natalizumab therapy.

4. Discussion

This exploratory study suggests that NTZ induces selective alterations of PPARβ/δ and PPARγ gene expression in PBMC of women with MS. This treatment is associated with peripheral sequestration of activated T cells and increased production of proinflammatory cytokines in the blood [8–10]. Inflammatory stimulation decreases PPARγ promoter activity and gene transcription and PPARγ agonists are anti-inflammatory and able to upregulate CD36 expression [1, 4, 5]. Therefore, the induction of systemic inflammation by NTZ could explain a decrease of PPARγ and CD36 gene expression in the PBMC of patients. Importantly, systemic inflammatory activity has been linked to the beneficial effects of NTZ in reducing biomarkers of intrathecal inflammation [8, 9]. It is well accepted that NTZ blocks α4β1 (VLA-4) integrin-mediated leukocyte transmigration to the CNS [8–10]. In this regard, it is interesting that PPARγ may regulate the expression of β1 integrin [13]. Moreover, in MS patients free of therapy, a pronounced elevation of PPARγ levels in the cerebrospinal fluid (CSF) was associated with increased intrathecal inflammation [14]. Overall, these data suggest that PPARγ-mediated processes may contribute to the mechanism of action of NTZ. In contrast, PPARβ/δ gene expression increased by this drug. PPARβ/δ has a complex role in immune regulation. Although PPARβ/δ agonists have strong anti-inflammatory effects, they may also induce some immune stimulatory components [15]. In experimental models, PPARβ/δ expression mediates distinctive mechanisms in suppressing CNS autoimmunity [3] and promoting myelination [7]. Therefore, the present results could indicate a link between PPARβ/δ upregulation and the protective effects of NTZ. It is remarkable that PPARα mRNA levels were unchanged in our cohort of MS women. In fact, PPARα expression was shown to modulate the production of proinflammatory cytokines and the development of EAE in males but not in females [2]. These findings suggest that it would be important to analyze whether PPARα also modulate gender-related differences in the mechanisms of action of NTZ therapy.

It was not unexpected that plasma neopterin levels increased at baseline, since most patients have been medicated with interferon beta. The mechanism of action of this treatment is known to increase this inflammatory marker of macrophage activation [11]. Notably, early in the course of NTZ therapy, plasma neopterin decreased to normal levels. As reported in most studies, plasma OPN was increased in our patients previously medicated with immunomodulators [12, 16]. Nevertheless, in contrast to neopterin, OPN levels were not significantly changed during the first six months on NTZ therapy. In a recent study, NTZ decreased OPN levels only after 12 months of treatment in correlation with an improvement of cognitive functions [12]. In this regard, it is of potential relevance that PPARγ and PPARα agonists have inhibitory effects on OPN gene expression [17, 18]. The systemic profile of T cells activation and cytokine production induced by NTZ treatment has been shown to be time-dependent and may change differently in single subjects [9, 10]. A major limitation of the present results concerns the small size of the studied population and the short follow-up period of treatment. Therefore, they do not exclude a role of PPAR in modulating patients’ response to this therapy. This should be tested in a larger sample cohort under a longer period of treatment and including other cytokine measurements and imaging data. A major concern associated with the continuation of NTZ therapy regards the increased risk for latent virus-infection activation, including the occurrence of progressive multifocal leukoencephalopathy. In the present context, it is to note that plasma OPN is especially increased in HIV-infected patient displaying cognitive complains [19] and that PPARγ and PPARα agonists may protect against HIV-induced inflammatory responses [20].

In conclusion, our findings suggest that NTZ therapy induces selective alterations of PPAR-mediated processes in circulating immune cells. These results need to be confirmed in a larger cohort of patients and longer follow-up periods of treatment. Along the reviewed data, they suggest that PPAR should be considered as potential useful biomarkers of MS patient response to NTZ therapy.

Competing Interests

The authors declare that they have no competing interests.

Authors’ Contributions

Véronique Ferret-Sena, Alexandra Maia e Silva, Inês Cavaleiro, and Bruno Derudas contributed to the laboratory analysis and revised the manuscript. Armando Sena contributed to the study design, acquisition of data, and writing the manuscript. José Vale contributed to the acquisition of data and revised the manuscript. Giulia Chinetti-Gbaguidi and Bart Staels contributed to supervision of the study and writing the manuscript. All authors read and approved the final manuscript.

Acknowledgments

The authors thank Dr J. C. Vasconcelos for assistance with statistical analyses and critical review of the manuscript. This work was supported by Biogen Idec (Natalippar project).

References

E. Rigamonti, G. Chinetti-Gbaguidi, and B. Staels, “Regulation of macrophage functions by PPAR-α, PPAR-γ, and LXRs in mice and men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 6, pp. 1050–1059, 2008.

S. E. Dunn, S. Ousman, A. R. Sobel et al., “Peroxisome Proliferator-Activated Receptor (PPAR) α expression in T cells mediates gender differences in development of T cell-mediated autoimmunity,” The Journal of Experimental Medicine, vol. 204, no. 2, pp. 321–330, 2007.

S. E. Dunn, R. Bhat, D. S. Straus et al., “Peroxisome proliferator-activated receptor δ limits the expansion of pathogenic Th cells during central nervous system autoimmunity,” The Journal of Experimental Medicine, vol. 207, no. 8, pp. 1599–1608, 2010.

S. Hucke, J. Floßdorf, B. Grützke et al., “Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor γ,” Brain, vol. 135, no. 5, pp. 1586–1605, 2012.

L. Klotz, M. Schmidt, T. Giese et al., “Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor γ levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients,” Journal of Immunology, vol. 175, no. 8, pp. 4948–4955, 2005.

C. C. Kaiser, D. K. Shukla, G. T. Stebbins et al., “A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis,” Journal of Neuroimmunology, vol. 211, no. 1-2, pp. 124–130, 2009.

M. Jana, S. Mondal, F. J. Gonzalez, and K. Pahan, “Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-β,” Journal of Biological Chemistry, vol. 287, no. 41, pp. 34134–34148, 2012.

M. Khademi, L. Bornsen, F. Rafatnia et al., “The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers,” European Journal of Neurology, vol. 16, no. 4, pp. 528–536, 2009.

P. Kivisäkk, B. C. Healy, V. Viglietta et al., “Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells,” Neurology, vol. 72, no. 22, pp. 1922–1930, 2009.

K. Kimura, M. Nakamura, W. Sato et al., “Disrupted balance of T cells under natalizumab treatment in multiple sclerosis,” NeurologyⓇ Neuroimmunology & Neuroinflammation, vol. 3, no. 2, p. e210, 2016.

A. Sena, K. Bendtzen, M. J. Cascais, R. Pedrosa, V. Ferret-Sena, and E. Campos, “Influence of apolipoprotein E plasma levels and tobacco smoking on the induction of neutralising antibodies to interferon-beta,” Journal of Neurology, vol. 257, no. 10, pp. 1703–1707, 2010.

P. Iaffaldano, M. Ruggieri, R. G. E. Viterbo, M. Mastrapasqua, and M. Trojano, “The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis,” Brain, behavior, and immunity, vol. 35, pp. 176–181, 2014.

W. Han, H. Zhao, B. Jiao, and F. Liu, “EPA and DHA increased PPARγ expression and deceased integrin-linked kinase and integrin β1 expression in rat glomerular mesangial cells treated with lipopolysaccharide,” BioScience Trends, vol. 8, no. 2, pp. 120–125, 2014.

L. Szalardy, D. Zadori, E. Tanczos et al., “Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosis,” Neuroscience Letters, vol. 554, pp. 131–134, 2013.

T. Adhikary, A. Wortmann, T. Schumann et al., “The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state,” Nucleic Acids Research, vol. 43, no. 10, pp. 5033–5051, 2015.

M. Comabella, I. Pericot, R. Goertsches et al., “Plasma osteopontin levels in multiple sclerosis,” Journal of Neuroimmunology, vol. 158, no. 1-2, pp. 231–239, 2005.

Y. Oyama, N. Akuzawa, R. Nagai, and M. Kurabayashi, “PPARγ ligand inhibits osteopontin gene expression through interference with binding of nuclear factors to A/T-rich sequence in THP-1 cells,” Circulation Research, vol. 90, no. 3, pp. 348–355, 2002.

T. Nakamachi, T. Nomiyama, F. Gizard et al., “PPARα agonists suppress osteopontin expression in macrophages and decrease plasma levels in patients with type 2 diabetes,” Diabetes, vol. 56, no. 6, pp. 1662–1670, 2007.

A. Brown, “Osteopontin: a key link between immunity, inflammation and the central nervous system,” Translational Neuroscience, vol. 3, no. 3, pp. 288–293, 2012.

W. Huang, G. B. Rha, M.-J. Han et al., “PPARα and PPARγ effectively protect against HIV-induced inflammatory responses in brain endothelial cells,” Journal of Neurochemistry, vol. 107, no. 2, pp. 497–509, 2008.